Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area

Table 3 Multivariate models without NLR for patients with advanced NPC

Endpoint	Variable	HR	95% CI for HR	P value
OS
	Age (≤ 45 vs. > 45)	1.64	1.25–2.14	< 0.001
	Sex (Male vs. Female)	1.3	0.90–1.88	0.158
	Smoking history (No vs. Yes)	1.09	0.82–1.46	0.553
	T stage (T1–2 vs. T3–4)	1.42	1.04–1.94	0.029
	N stage (N0–1 vs. N2–3)	2.84	2.18–3.69	< 0.001
DMFS
	Sex (Male vs. Female)	1.34	0.95–1.89	0.098
	N stage (N0–1 vs. N2–3)	3.49	2.64–4.61	< 0.001
LRFS
	Age (≤ 45 vs. > 45)	1.4	1.02–1.92	0.035
	N stage (N0–1 vs. N2–3)	1.35	0.97–1.88	0.077
PFS
	Age (≤ 45 vs. > 45)	1.42	1.15–1.77	0.001
	Family history (No vs. Yes)	1.17	0.92–1.50	0.205
	Smoking history (No vs. Yes)	1.11	0.89–1.38	0.34
	T stage (T1–2 vs. T3–4)	1.28	1.00–1.65	0.048
	N stage (N0–1 vs. N2–3)	2.24	1.81–2.78	< 0.001

Abbreviation: OS overall survival, DMFS distant metastasis-free survival, LRFS locoregional relapse-free survival, PFS progression-free survival, RT radiotherapy, CCRT concurrent chemoradiotherapy, NACT neoadjuvant chemotherapy, NLR neutrophil-to-lymphocyte ratio, HR rate ratio, CI confidence interval

ISSN: 1471-2407